Advanced Filters
noise

TOULOUSE Cedex, France Clinical Trials

A listing of TOULOUSE Cedex, France clinical trials actively recruiting patients volunteers.

Found 743 clinical trials
E Emmanuel Gonzales

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)

The key objectives of this low-intervention clinical study are to evaluate tolerability, long-term safety and long-term efficacy for patients with Alagille syndrome (ALGS) who are prescribed Livmarli.

2 years of age All Phase 4
A Amandine SAUBION

Proof of Concept Study on BP1.4979 Effect on Essential Tremor

The goal of this clinical trial is to learn if drug BP1.4979 works to treat essential tremors in adults. It will also learn about the safety of drug BP1.4979. The main questions it aims to answer are: Does the drug BP1.4979 reduce tremors in individuals with essential tremor? Do participants …

18 - 85 years of age All Phase 2
S Stéphanie Martinez, Dr

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

The hypothesize is that tepotinib is more effective than the investigator's choice of treatment in patients with MET-mutated NSCLC who have progressed after at least one first-line treatment. The main benefit concerns patient access to tepotinib. There is currently no access to a new-generation MET TKI in France for METex14 …

18 years of age All Phase 3
I Ingrid Plotton

Dexamethasone and Pregnancy: Maternal Effects

This study will analyze obstetric, endocrine and metabolic follow-up data in women treated with DEX. It will reveal the prevalence and importance of weight gain, insomnia, edema, stretch marks, arterial hypertension and gestational diabetes, describe pregnancy outcome, and analyze the corticotropic axis during and up to 3 months after pregnancy, …

18 years of age Female Phase N/A
V Victor SARRADIN

Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

This is a phase II, prospective, non-randomized, single-arm, multicentric study to evaluate the activity and safety of treatment with 4 cycles (instead of 6) of chemotherapy (platinum (cisplatin or carboplatin) and 5-Fluorouracil) in combination with pembrolizumab for the first-line treatment of CPS PD-L1 positive recurrent or metastatic head and neck …

18 years of age All Phase 2
J Julie CORTADELLAS

Autistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome

Prader-Willi Syndrome (PWS) is a rare neurodevelopmental disorder stemming from genetic damage in the 15q11-q13 region, leading to hypothalamic dysfunction. Individuals with PWS often exhibit social interaction challenges, intellectual deficits, significant eating disorders, mood disturbances, and sensory-related autistic features. Although PWS is recognized by DSM-5 as a genetic cause of …

3 - 16 years of age All Phase N/A
C Cyril Maire

Evaluation of a HA Dermal Filler in the Treatment of Lip Deformity

Early postnatal repair of cleft lip and palate aims at the development of the child through reconstruction of the face soon after birth. Cleft lip is the result of a defect in the fusion of the buds of the face by default of cell apoptosis of the embryonic neural crest …

18 years of age All Phase N/A
N Nassim KAMAR, MD

EVEROLD LONG TERM FOLLOW-UP

Long Term Follow up of EVEROLD study

18 years of age All Phase N/A
C CHRISTINE POITOU-BERNERT, MD

Effects of Transcutaneous Vagus Nerve Stimulation on Emotion Regulation and Executive Functioning in Prader-Willi Syndrome

The STIM-PRADER study aims to assess the effectiveness of auricular vagal neuromodulation therapy (aVNT) on emotional, behavioral, and cognitive domains impaired in Prader-Willi Syndrome (PWS). Currently, no treatment exists that addresses the multiple alterations associated with this rare neurodevelopmental disorder that significantly impact patients and their families. We will investigate …

18 years of age All Phase N/A
N Nicolas GUIBERT, MCU-PH

Genotyping of Ebus-tbna Supernant Cell-free Dna in Nsclc

The wide uptake of "liquid biopsy" diagnostics in the care of advanced cancer patients highlights the desire for improved access to tumor allowing accurate tumor genotyping (1). Genotyping of plasma cfDNA is now routine for detection of EGFR driver mutations at diagnosis of NSCLC, or for detection of the EGFR …

18 - 65 years of age All Phase N/A

Simplify language using AI